La Gazette du LABORATOIRE Brèves
La Gazette du Laboratorie,
2021-06-18 Thérapie cellulaire CAR T : Nouvelles données de l’essai ZUMA-3 dans la leucémie aigüe lymphoblastique /GILEAD …
Health Canada Approves Amgen's BLINCYTO (blinatumomab) For The Treatment Of Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Biospace,
BLINCYTO is the First-and-Only Bispecific CD19-Directed CD3 T-Cell Engager (BiTE ® ) Immunotherapy Approved by Health Canada…
Amgen Receives Positive Opinions For Two New Treatment Options For Patients With Blood Cancer In Europe
Biospace,
THOUSAND OAKS, Calif., Sept. 25, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal…
Amgen Receives CHMP Positive Opinions For Two New Treatment Options For Patients With Blood Cancer In Europe
International Business Times,
THOUSAND OAKS, Calif., Sept. 25, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal…
News story from Reuters on Friday 25 September 2015
Reuters,
Amgen Receives CHMP Positive Opinions For Two New Treatment Options For Patients With Blood Cancer In Europe
Bioportfolio,
THOUSAND OAKS, Calif., Sept. 25, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal…